

AR226- 3421



000223

From: Barbara J Dawson on 10/19/2000 12:06 PM
 To: Beth F Basham/AE/DuPont@DuPont, Aaron Chen/AE/DuPont@DuPont, Michael J
 Daly/AE/DuPont@DuPont, Nicholas J DeStefano/AE/DuPont@DuPont, Mary Ann
 Hayes/DuPont@DuPont, James R Koterski/AE/DuPont@DuPont, Irene A Legiec/AE/DuPont@DuPont,
 Richard J Libutti/DuPont@DuPont, Douglas A Paine/AE/DuPont@DuPont, Michael L
 Szep/AE/DuPont@DuPont

cc: [REDACTED]

Subject: C8 Medical Surveillance - Draft Letter to Participants

Here is a copy of the letter we plan to send to participants as approved by [REDACTED]

----- Forwarded by Barbara J Dawson/AE/DuPont on 10/19/2000 12:04 PM -----

From: Barbara J Dawson on 10/10/2000 10:58 AM
 To:
 cc:
 bcc:
 Subject: C8 Medical Surveillance - Draft Letter to Participants

Last year, you participated in a baseline C8 medical surveillance program which included analysis of your blood for perfluorooctanoate (PFOA) and total fluorine. You were asked to participate in this program because your job assignment at that time included the potential for exposure to C8. We are now ready to conduct the post campaign surveillance. Medical will draw additional blood samples which will be analyzed for PFOA and total fluorine. These results will be compared to your baseline results to determine if you received any exposure to this chemical during the past year. We will share the results and interpretation of the data with you.

Please contact your unit S&OH coordinator to make arrangements for an appointment at Medical. Blood will be drawn over the next few weeks on Wednesday, Thursday and Friday. Unit S&OH coordinators are:

[REDACTED]

If you have any questions, please contact me or your unit S&OH coordinator.

Company Sanitized. Does not contain TSCA CBI